摘要
目的 评价奥氮平治疗精神分裂症的临床疗效与安全性。方法 80例精神分裂症患者随机分成2组,分别给予奥氮平与氯氮平治疗12周,采用PANSS评价临床疗效,TESS评价不良反应。结果 全部病人完成疗程,奥氮平组治疗前后PANSS减分率42.4％,有效率为82.5％;氯氮平组治疗前后PANSS减分率37.5％,有效率为70％,未见严重的药物不良反应,安全性好。结论 奥氮平是一种有效的治疗精神分裂症的药物。
Objectives: To evaluate the efficacy and safety of olanzapine in the treatment of schizophrenia. Method: Eighty patients with schizophrenia were randomly assigned into the treatment groups of olanzapine or clozapine for 12 weeks. PANSS and TESS scales were used to measure their efficacy and safety. Results: 82. 5% patients responded to olanzapine treatment while 70. 0% responded to clozapine (X2 = 21. 80, p=0. 40) ; The total PANSS scores were decreased by 42. 4% after 12 weeks of olanzapine treatment while there were 37. 5% reduction in clozapine group. A significant difference was found in the profile of side effects between the two groups. Conclusion: Olanzapine is effective in treating schizophrenia.
出处
《上海精神医学》
2000年第3期143-145,共3页
Shanghai Archives of Psychiatry
